Abstract
Olaparib improved PFS and OS across subgroups of BRCA1/2mut #prostatecancer patients in the PROFOUND phase III trial.
Trial registration:
ClinicalTrials.gov NCT02987543.
Publication types
-
Clinical Trial, Phase III
MeSH terms
-
BRCA1 Protein / genetics
-
BRCA2 Protein / genetics
-
Humans
-
Kaplan-Meier Estimate
-
Male
-
Phthalazines / therapeutic use
-
Piperazines / therapeutic use
-
Prostatic Neoplasms, Castration-Resistant* / drug therapy
-
Prostatic Neoplasms, Castration-Resistant* / genetics
Substances
-
BRCA1 Protein
-
BRCA1 protein, human
-
BRCA2 Protein
-
BRCA2 protein, human
-
olaparib
-
Phthalazines
-
Piperazines
Associated data
-
ClinicalTrials.gov/NCT02987543